{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_relationships_comments in Relationship Comments (approximate match)
Status:
US Approved OTC
Source:
21 CFR 357.210(a) cholecystokinetic corn oil, aqueous emulsion
Source URL:
First approved in 1978
Source:
NDA018081
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:labafenogene marselecobac [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00397943: Phase 2 Interventional Completed Tuberculosis
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First approved in 1972
Source:
BLA102192
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03530124: Phase 4 Interventional Completed Apnea
(2018)
Source URL:
First approved in 2021
Source:
Jointox BB by Energique, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01628705: Phase 4 Interventional Completed Nutritional and Metabolic Disease
(2007)
Source URL:
First approved in 2009
Source:
Sumaxin Cleansing Pads by Medimetriks Pharmaceuticals, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Hair Loss and Scalp Moisturizing by Selenia
Source URL:
First approved in 2000
Source:
NDA210895
Source URL:
Class:
STRUCTURALLY DIVERSE